All
NCI-Designated Cancer Centers Yield Improved Mortality Rates in Acute Myeloid Leukemia
May 3rd 2018As suspected, the average early mortality rate improved overall during the study period. But while evaluating the data, researchers noticed something interesting about the difference in early mortality at the NCI-designated cancer centers compared to non-NCI-designated cancer centers.
FDA Approves CAR-T Cell Therapy for Diffuse Large B-Cell Lymphoma
May 2nd 2018The Food and Drug Administration (FDA) approved Kymriah (tisagenlecleucel) – a CAR-T cell therapy – for the treatment of adult patients who have relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have relapsed or are ineligible for an autologous stem cell transplant (ASCT).
FDA Approves Combination for Adjuvant Treatment of Melanoma Subtypes
May 1st 2018The combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib) was granted Food and Drug Administration (FDA) approval for the treatment of patients with BRAF V600E– or V600K–positive stage 3 melanoma following complete resection.
Cemiplimab Granted Priority Review for Skin Cancer Treatment
April 30th 2018The Food and Drug Administration (FDA) granted a priority review to a biologics license application (BLA) for an immunotherapy agent – cemiplimab – to be used to treat metastatic cutaneous squamous cell carcinoma (a type of skin cancer; CSCC) or patients with locally advanced CSCC who are not eligible for surgery.
Healing Waters: Reflecting on the Lessons of Survivorship
April 30th 2018When I contemplate this latest benchmark in my life, my 15th year surviving stage 3b breast cancer, I confess there are times when I feel like it was just yesterday the Trickster Coyote – the Native American mythical creature of evil and bad omen – blindsided me, bent on taking me down in the one sacred place I felt I could take refuge from the world: my home.
FDA Grants Priority Review for Immunotherapy-Based Lung Cancer Combination
April 30th 2018The Food and Drug Administration (FDA) granted a priority review to a supplemental biologics license application (sBLA) for frontline Keytruda (pembrolizumab) for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC), according to Merck (MSD), the manufacturer of the PD-1 inhibitor.
Chronic Illness and Disability: Living With a Long-Term Diagnosis
April 27th 2018For those of us living with (and taking care of) people living with brain tumors, cancers and other diseases that become chronic, life's challenges begin to shift, as do our outlooks. It is important for us to be able to love our bodies, our disabilities, and for the world to make space for all sorts of bodies to exist.